Evidence map›Paper›PMID 36139051›Full record

ReviewBiomolecules2022

SARS-CoV-2 and Skin: New Insights and Perspectives.

Gerardo Cazzato, Eliano Cascardi, Anna Colagrande, Caterina Foti, Alessandra Stellacci, Maricla Marrone, Giuseppe Ingravallo, Francesca Arezzo, Vera Loizzi, Antonio Giovanni Solimando and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Skin as a Potential Entry Point for SARS-CoV-2 Virus.International journal of molecular sciences · 2026
    Article
  2. SKIN AS A POTENTIAL ENTRY POINT FOR SARS-COV-2.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. The "Magnificent Seven" in Oral and Systemic Health against COVID-19.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Gerardo CazzatoSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-0325-4316
Eliano CascardiDepartment of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0003-1287-4285
Anna ColagrandeSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.
Caterina FotiSection of Dermatology, Department of Biomedical Sciences and Oncology (DIMO), University of Bari "Aldo Moro", 70124 Bari, Italy.
Alessandra StellacciSection of Legal Medicine, Department of Interdisciplinary Medicine, Bari Policlinico Hospital, University of Bari, 70124 Bari, Italy.ORCID 0000-0002-7397-0097
Maricla MarroneSection of Legal Medicine, Department of Interdisciplinary Medicine, Bari Policlinico Hospital, University of Bari, 70124 Bari, Italy.ORCID 0000-0002-1058-7269
Giuseppe IngravalloSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-4792-3545
Francesca ArezzoSection of Gynecology and Obstetrics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", 70124 Bari, Italy.
Vera LoizziSection of Gynecology and Obstetrics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-4006-6421
Antonio Giovanni SolimandoSection of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-2293-9698
Paola ParentePathology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71100 San Giovanni Rotondo, Italy.ORCID 0000-0003-0591-6723
Eugenio MaioranoSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-0472-5338
Gennaro CormioOncology Unit IRCCS Istituto Tumori Giovanni Paolo II and Department of Interdisciplinary Medicine (DIM), University of Bari, 70124 Bari, Italy.ORCID 0000-0001-5745-372X
Angelo VaccaSection of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-4567-8216
Leonardo RestaSection of Molecular Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-4335-4776
University of Bari Aldo Moro · ITCandiolo Cancer Institute · ITCasa Sollievo della Sofferenza · ITIstituto Tumori Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic has disrupted global health systems and brought the entire globe to its knees. Although born as a disease of the respiratory system, COVID-19 can affect different parts of the body, including the skin. Reports of ongoing skin manifestations of COVID-19 have gradually multiplied, pushing researchers to investigate the etiopathogenic mechanisms underlying these phenomena in more depth. In an attempt to investigate the possible association between SARS-CoV-2, ACE2, TMPRSS2 and skin manifestations, we performed immunohistochemical investigations of the ACE2 receptor and TMPRSS2 in nine skin samples from SARS-CoV-2-positive patients compared to a cohort of healthy controls. Furthermore, after consulting public databases regarding ACE2 mRNA expression in various cell populations resident in the skin, we conducted a literature review aimed at outlining the current state of this topic. We did not find statistically different immuno-expression of ACE2 and TMPRSS2 between the group of SARS-CoV-2-positive patients (nine skin biopsies) and the control group. Regarding ACE2, major immunolabeling was present in the epidermal keratinocytes and, rarely, in the fibroblasts and in the adenomeres of the eccrine sweat glands. Regarding the immune expression of TMPRSS2, we found no significant differences between the two groups, with a weak immune staining only in some skin cytotypes. From the review of the literature, we isolated 35 relevant articles according to the inclusion criteria adopted. ACE2 appears to be a target of SARS-CoV-2, although, other receptor molecules may potentially be implicated, such as TMPRSS2. Future studies with large cases and different molecular investigative methods are needed to further elucidate the mechanisms underlying the skin manifestations of SARS-CoV-2.

Indexed as

COVID-19Skin DiseasesAngiotensin-Converting Enzyme 2HumansRNA, MessengerSARS-CoV-2Serine EndopeptidasesACE2 protein, humanAngiotensin-Converting Enzyme 2RNA, MessengerSerine EndopeptidasesTMPRSS2 protein, humanACE2dermatopathologymanifestationpandemicSARS-CoV-2skinTMPRSS2

Identifiers

PMID36139051
PMCPMC9496354
OpenAlexW4294343786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.